Aristotelis Nastos
Angel Investor @ BioMedPartners
Cologne, Germany
Aristotelis Nastos is a seed investor at BioMedPartners in Cologne focused on Biotechnology and Health Care. Dr. Aristotelis Nastos - Head of Life Sciences & Cleantech @ NRW.BANK
- Total investments:
- 3
- Last investment:
- Lead investor:
- 100%
Last updated:
For AI agents: llms.txt
Industries Aristotelis Nastos invests in
Stages Aristotelis Nastos invests in
Countries Aristotelis Nastos invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (100%)
- Health Care 2 (67%)
- Medical 1 (33%)
- Chemical 1 (33%)
- Oncology 1 (33%)
Stage
- Seed 1 (33%)
- Series A 1 (33%)
- Venture - Series Unknown 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism. | $10.4M / Seed / Mar 17, 2026 | ||
| T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designedto improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care. | $20M / Series A / Dec 17, 2025 | ||
| CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system.CAP-Go enables the production of proteins “beyond antibodies”. Complex, glycosylated proteins represent a significant portion of the human proteome and are notoriously difficult to express in conventional cell lines such asCHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns. | Venture - Series Unknown / Jul 27, 2021 |
Co-Investors
About BioMedPartners
BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
BioMedPartners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Fiona Lauscher
Office Manager
|
|||
Karl Deres
Venture Partner
|
|||
Markus Hosang
General Partner
|
|||
Patrick Burgermeister
Partner
|
|||
Stefan Fäs
Chief Financial Officer & Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Aristotelis Nastos invest in?
Aristotelis Nastos invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Series A stage. Most of the 3 investments tracked by Shizune back companies in Germany. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Aristotelis Nastos?
Public channels for Aristotelis Nastos include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Aristotelis Nastos last invest?
The most recent investment recorded for Aristotelis Nastos closed in Mar 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
